Recent Updates
Recently added Catalysts

EVO756, Dose 1

Phase 2

Migraine | Small molecule | Neurology |Evommune, Inc.|Last Updated: Jun 1, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment330
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07616128Study of EVO756 in Adults With MigrainePHASE2 NOT YET_RECRUITING 330 — — Jun 1, 2026Nov 1, 2027Jun 1, 2026 - —
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Mean change from baseline in the number of monthly migraine days (MMD)
Last month of the 12-week treatment period
Secondary Endpoints
Mean change from baseline in the number of MMD
Weeks 4, 8, and across the treatment period (up to 12-weeks)
Mean change from baseline in the number of monthly headache days (MHD)
Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Proportion of subjects achieving ≥50% and ≥75% reduction in MMD
Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Dose 1EXPERIMENTALOrally administered EVO756, Dose 1 (Daily)
Dose 2EXPERIMENTALOrally administered EVO756, Dose 2 (Daily)
PlaceboPLACEBO_COMPARATORPlacebo control (Daily)
Interventions
NameTypeDescription
EVO756, Dose 1DRUGOrally administered EVO756, Dose 1 (Daily)
EVO756, Dose 2DRUGOrally administered EVO756, Dose 2 (Daily)
PlaceboDRUGPlacebo Control (Daily)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 64 Years
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: * Adults aged 18 to \<65 years * Migraine with or without aura, per ICHD-3 criteria * History of failure with prior preventive migraine treatments * Not currently using migraine preventive therapy Key Exclusion Criteria: * Difficulty distinguishing migraine from other head...

Unlock Eligibility Criteria
Competitive Landscape -Migraine 32 trials
CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV15PHASE3Atogepant, Topiramate, Ubrogepant, MEDI0618
Pfizer Inc.PFE9PHASE3Rimegepant, Rimegepant/BHV3000, Zavegepant, Various, Rimegepant for acute migraine treatment
Eli Lilly and CompanyLLY2PHASE3Galcanezumab
Amgen Inc.AMGN2PHASE3Erenumab Dose 1, erenumab-aooe
Ki Health Partners. LLCRVNC1 — Daxibotulinumtonix A
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJun 2, 2026NCT07616128NEW_TRIAL: changed
LOWJun 2, 2026NCT07616128NEW_TRIAL: changed
LOWJun 2, 2026NCT07616128NEW_TRIAL: changed